Key stats
About ALPS Medical Breakthroughs ETF
Home page
Inception date
Dec 31, 2014
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
ALPS Advisors, Inc.
Distributor
ALPS Portfolio Solutions Distributor, Inc.
SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the funds index was Poliwogg Medical Breakthroughs Index, which has the same strategies.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.87%
Health Technology99.30%
Health Services0.55%
Bonds, Cash & Other0.13%
Mutual fund0.15%
Cash−0.02%
Stock breakdown by region
North America74.47%
Europe22.41%
Asia3.11%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
SBIO invests in stocks. The fund's major sectors are Health Technology, with 99.33% stocks, and Health Services, with 0.55% of the basket. The assets are mostly located in the North America region.
SBIO top holdings are Verona Pharma plc Sponsored ADR and Alkermes Public Limited Company, occupying 5.72% and 4.13% of the portfolio correspondingly.
SBIO last dividends amounted to 1.17 USD. The year before, the issuer paid 0.07 USD in dividends, which shows a 93.94% increase.
SBIO assets under management is 84.34 M USD. It's risen 2.47% over the last month.
SBIO fund flows account for −9.59 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, SBIO pays dividends to its holders with the dividend yield of 3.79%. The last dividend (Dec 26, 2024) amounted to 1.17 USD. The dividends are paid annually.
SBIO shares are issued by SS&C Technologies Holdings, Inc. under the brand ALPS. The ETF was launched on Dec 31, 2014, and its management style is Passive.
SBIO expense ratio is 0.50% meaning you'd have to pay 0.50% of your investment to help manage the fund.
SBIO follows the S-Network Medical Breakthroughs Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
SBIO invests in stocks.
SBIO price has risen by 4.58% over the last month, and its yearly performance shows a −7.46% decrease. See more dynamics on SBIO price chart.
NAV returns, another gauge of an ETF dynamics, showed a 0.52% increase in three-month performance and has decreased by −5.97% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 0.52% increase in three-month performance and has decreased by −5.97% in a year.
SBIO trades at a premium (0.08%) meaning the ETF is trading at a higher price than the calculated NAV.